Skip to main content
Fig. 2 | Breast Cancer Research

Fig. 2

From: KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene

Fig. 2

Identification of a KLF4-regulated protein signature reveals EGFR as a downstream target. a Western blot confirming the upregulation of KLF4 and its downstream target, E-cadherin, in MDA-MB-231 cells after AdGFP or AdKLF4 infection. b Reverse phase protein array heatmap showing differentially expressed genes after AdGFP or AdKLF4 infection in MDA-MB-231 cells. This analysis was completed as one experiment in duplicate. Proteins whose expression fold change was significantly different (p < 0.05) between AdKLF4 and AdGFP are shown. Red arrows indicate suppression of EGFR and phosphorylated EGFR by KLF4 overexpression while the green arrow identifies upregulated E-cadherin following KLF4 overexpression. c Western blot confirming EGFR repression in MDA-MB-231 cells infected with AdKLF4 compared to those infected with AdGFP. d Western blot analysis of EGFR expression across eight breast epithelial cell lines: MCF10A (10A), MCF7, T47D, SKBR3, HCC1143 (1143), SUM159, HCC70, MDA-MB-468 (468), and MDA-MB-231 (231). e Inverse correlation between KLF4 and EGFR protein in the eight breast epithelial cell lines, r2 = 0.8542. *SKBR3 cell line

Back to article page